Asset Details
Do you wish to reserve the book?
Mechanism and therapeutic effect of umbilical cord mesenchymal stem cells in inflammatory bowel disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Mechanism and therapeutic effect of umbilical cord mesenchymal stem cells in inflammatory bowel disease
Do you wish to request the book?
Mechanism and therapeutic effect of umbilical cord mesenchymal stem cells in inflammatory bowel disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Mechanism and therapeutic effect of umbilical cord mesenchymal stem cells in inflammatory bowel disease
2019
Overview
Inflammatory bowel disease (IBD) is a persistent and chronic disease that is characterized by destructive gastrointestinal (GI) inflammation. Researchers are trying to identify and develop new and more effective treatments with no side effects. Acute and chronic mouse models of IBD were established using dextran sulfate sodium (DSS) solution. To evaluate the efficacy and mechanism, umbilical cord mesenchymal stem cells (UCMSCs) were obtained from Kunming (KM) mice and humans. In the chronic IBD study, the survival rates of the normal control, model, mouse UCMSC (mUCMSC) and human UCMSC (hUCMSC) groups were 100%, 40%, 86.7%, and 100%, respectively. The histopathological scores of the normal control, intraperitoneal injection, intravenous treatment, and model groups were 0.5 ± 0.30, 5.9 ± 1.10, 8.7 ± 1.39, and 8.8 ± 1.33 (p = 0.021). UCMSCs promoted the expression of the intestinal tight junction protein occludin, downregulated the protein expression of the autophagy marker LC3A/B in colon tissue, and upregulated the expression of VEGF-A and VEGFR-1 at the injured site. This study provides an experimental model for elucidating the therapeutic effects of UCMSCs in IBD. We provide a theoretical basis and method for the clinical treatment of IBD using UCMSCs.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ 13/100
/ 13/107
/ 13/51
/ 38
/ 38/1
/ 38/35
/ 38/77
/ 42
/ 42/100
/ 692/4020
/ 82
/ 82/83
/ Animals
/ Colon
/ Dextran
/ Humanities and Social Sciences
/ Humans
/ Inflammatory Bowel Diseases - therapy
/ Mesenchymal Stem Cell Transplantation
/ Mice
/ Science
/ Sodium
/ Survival
/ Tight Junctions - metabolism
/ Vascular endothelial growth factor
/ Vascular Endothelial Growth Factor A - metabolism
/ Vascular Endothelial Growth Factor Receptor-1 - metabolism
